{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T11:05:21Z","timestamp":1779102321419,"version":"3.51.4"},"reference-count":90,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,1,2]],"date-time":"2019-01-02T00:00:00Z","timestamp":1546387200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001279","name":"Great Ormond Street Hospital Charity","doi-asserted-by":"publisher","award":["W1090"],"award-info":[{"award-number":["W1090"]}],"id":[{"id":"10.13039\/501100001279","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"crossref","award":["C1188\/A4614"],"award-info":[{"award-number":["C1188\/A4614"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100011692","name":"Children's Cancer and Leukaemia Group","doi-asserted-by":"publisher","award":["CCLGA 2017 02"],"award-info":[{"award-number":["CCLGA 2017 02"]}],"id":[{"id":"10.13039\/100011692","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Great Ormond Street Hospital Biomedical Research Centre"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Drugs"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1007\/s40272-018-0323-z","type":"journal-article","created":{"date-parts":[[2019,1,2]],"date-time":"2019-01-02T04:51:07Z","timestamp":1546404667000},"page":"1-13","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Pharmacotherapeutic Management of Wilms Tumor: An Update"],"prefix":"10.1007","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9674-8870","authenticated-orcid":false,"given":"Radna Minou","family":"Oostveen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2384-9475","authenticated-orcid":false,"given":"Kathy","family":"Pritchard-Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,1,2]]},"reference":[{"issue":"6","key":"323_CR1","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/S1470-2045(17)30186-9","volume":"18","author":"E Steliarova-Foucher","year":"2017","unstructured":"Steliarova-Foucher E, Colombet M, Ries LAG, Moreno F, Dolya A, Bray F, et al. International incidence of childhood cancer, 2001\u201310: a population-based registry study. Lancet Oncol. 2017;18(6):719\u201331.","journal-title":"Lancet Oncol"},{"issue":"2","key":"323_CR2","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1111\/cas.13457","volume":"109","author":"K Nakata","year":"2018","unstructured":"Nakata K, Ito Y, Magadi W, Bonaventure A, Stiller CA, Katanoda K, et al. Childhood cancer incidence and survival in Japan and England: a population-based study (1993\u20132010). Cancer Sci. 2018;109(2):422\u201334.","journal-title":"Cancer Sci"},{"issue":"9","key":"323_CR3","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1136\/jmg.2006.041723","volume":"43","author":"RH Scott","year":"2006","unstructured":"Scott RH, Stiller CA, Walker L, Rahman N. Syndromes and constitutional chromosomal abnormalities associated with Wilms tumour. J Med Genetics. 2006;43(9):705\u201315.","journal-title":"J Med Genetics"},{"key":"323_CR4","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.ejca.2016.09.005","volume":"68","author":"J Brok","year":"2016","unstructured":"Brok J, Treger TD, Gooskens SL, van den Heuvel-Eibrink MM, Pritchard-Jones K. Biology and treatment of renal tumours in childhood. Eur J Cancer. 2016;68:179\u201395.","journal-title":"Eur J Cancer"},{"issue":"10","key":"323_CR5","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1038\/ng.3940","volume":"49","author":"S Gadd","year":"2017","unstructured":"Gadd S, Huff V, Walz AL, Ooms AHAG, Armstrong AE, Gerhard DS, et al. A Children\u2019s Oncology Group and TARGET initiative exploring the genetic landscape of wilms tumor. Nature Genetics. 2017;49(10):1487\u201394.","journal-title":"Nature Genetics"},{"issue":"5","key":"323_CR6","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1111\/cas.12910","volume":"107","author":"C Deng","year":"2016","unstructured":"Deng C, Dai R, Li X, Liu F. Genetic variation frequencies in Wilms\u2019 tumor: a meta-analysis and systematic review. Cancer Sci. 2016;107(5):690\u20139.","journal-title":"Cancer Sci"},{"issue":"2","key":"323_CR7","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1007\/s13277-015-4514-8","volume":"37","author":"X Yu","year":"2016","unstructured":"Yu X, Li Z, Chan MTV, Wu WKK. The roles of microRNAs in Wilms\u2019 tumors. Tumor Biol. 2016;37(2):1445\u201350.","journal-title":"Tumor Biol"},{"issue":"17","key":"323_CR8","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1016\/j.ejca.2007.07.022","volume":"43","author":"DM Green","year":"2007","unstructured":"Green DM. Controversies in the management of Wilms tumour\u2014immediate nephrectomy or delayed nephrectomy? Eur J Cancer. 2007;43(17):2453\u20136.","journal-title":"Eur J Cancer"},{"issue":"15","key":"323_CR9","doi-asserted-by":"publisher","first-page":"2554","DOI":"10.1016\/j.ejca.2006.05.026","volume":"42","author":"C Mitchell","year":"2006","unstructured":"Mitchell C, Pritchard-Jones K, Shannon R, Hutton C, Stevens S, Machin D, et al. Immediate nephrectomy versus preoperative chemotherapy in the management of non-metastatic Wilms\u2019 tumour: results of a randomised trial (UKW3) by the UK Children\u2019s Cancer Study Group. Eur J Cancer. 2006;42(15):2554\u201362.","journal-title":"Eur J Cancer"},{"issue":"27","key":"323_CR10","doi-asserted-by":"publisher","first-page":"2999","DOI":"10.1200\/JCO.2015.62.1888","volume":"33","author":"JS Dome","year":"2015","unstructured":"Dome JS, Graf N, Geller JI, Fernandez CV, Mullen EA, Spreafico F, et al. Advances in Wilms tumor treatment and biology: progress through international collaboration. J Clin Oncol. 2015;33(27):2999\u20133007.","journal-title":"J Clin Oncol"},{"key":"323_CR11","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/978-3-662-44003-2","volume-title":"Renal tumors of childhood","author":"K Pritchard-Jones","year":"2014","unstructured":"Pritchard-Jones K, Dome JS. Renal tumors of childhood. Berlin, Heidelberg: Springer; 2014. p. 53\u201376."},{"issue":"11","key":"323_CR12","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/s41585-018-0100-3","volume":"15","author":"GM Vujani\u0107","year":"2018","unstructured":"Vujani\u0107 GM, Gessler M, Ooms AHAG, Collini P, Coulomb-l\u2019Hermine A, D\u2019Hooghe E, et al. The UMBRELLA SIOP\u2013RTSG 2016 Wilms tumour pathology and molecular biology protocol. Nature Rev Urol. 2018;15(11):693\u2013701.","journal-title":"Nature Rev Urol."},{"key":"323_CR13","doi-asserted-by":"publisher","first-page":"670","DOI":"10.12688\/f1000research.10760.1","volume":"6","author":"RI Lopes","year":"2017","unstructured":"Lopes RI, Lorenzo A. Recent advances in the management of Wilms\u2019 tumor. F1000Research. 2017;6:670.","journal-title":"F1000Research"},{"issue":"15","key":"323_CR14","doi-asserted-by":"publisher","first-page":"2352","DOI":"10.1200\/JCO.2005.04.7852","volume":"24","author":"JS Dome","year":"2006","unstructured":"Dome JS, Cotton CA, Perlman EJ, Breslow NE, Kalapurakal JA, Ritchey ML, et al. Treatment of anaplastic histology Wilms\u2019 tumor: results from the fifth national Wilms\u2019 tumor study. J Clin Oncol. 2006;24(15):2352\u20138.","journal-title":"J Clin Oncol"},{"issue":"29","key":"323_CR15","doi-asserted-by":"publisher","first-page":"7312","DOI":"10.1200\/JCO.2005.01.2799","volume":"23","author":"PE Grundy","year":"2005","unstructured":"Grundy PE, Breslow NE, Li S, Perlman E, Beckwith JB, Ritchey ML, et al. Loss of heterozygosity for chromosomes 1p and 16q Is an Adverse prognostic factor in favorable-histology Wilms tumor: a report from the national Wilms tumor study group. J Clin Oncol. 2005;23(29):7312\u201321.","journal-title":"J Clin Oncol"},{"issue":"12","key":"323_CR16","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1586\/era.09.159","volume":"9","author":"F Spreafico","year":"2009","unstructured":"Spreafico F, Pritchard Jones K, Malogolowkin MH, Bergeron C, Hale J, de Kraker J, et al. Treatment of relapsed Wilms tumors: lessons learned. Expert Rev Anticancer Therapy. 2009;9(12):1807\u201315.","journal-title":"Expert Rev Anticancer Therapy"},{"issue":"5","key":"323_CR17","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1097\/00000658-193811000-00010","volume":"108","author":"WE Ladd","year":"1938","unstructured":"Ladd WE. Embryoma of the kidney (Wilms\u2019 tumor). Ann Surg. 1938;108(5):885\u2013902.","journal-title":"Ann Surg"},{"key":"323_CR18","first-page":"843","volume-title":"Pediatrics","author":"J Randolph","year":"1950","unstructured":"Randolph J. Treatment of mixed tumors of the kidney in childhood. In: Gross RE, Neuhauser EBD, editors. Pediatrics, vol. 6. 1950. p. 843\u201352 (1998;102(Supplement 1):209\u201310)."},{"issue":"1","key":"323_CR19","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1002\/1097-0142(197907)44:1<52::AID-CNCR2820440110>3.0.CO;2-I","volume":"44","author":"DM Green","year":"1979","unstructured":"Green DM, Jaffe N, Paed D. The role of chemotherapy in the treatment of Wilms\u2019 tumor. Cancer. 1979;44(1):52\u20137.","journal-title":"Cancer"},{"issue":"2","key":"323_CR20","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1002\/1097-0142(19900715)66:2<264::AID-CNCR2820660212>3.0.CO;2-Z","volume":"66","author":"E Larsen","year":"1990","unstructured":"Larsen E, Perez-Atayde A, Green DM, Retik A, Clavell LA, Sallan SE. Surgery only for the treatment of patients with stage I (Cassady) Wilms\u2019 tumor. Cancer. 1990;66(2):264\u20136.","journal-title":"Cancer"},{"issue":"1","key":"323_CR21","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1200\/JCO.1993.11.1.91","volume":"11","author":"DM Green","year":"1993","unstructured":"Green DM, Breslow NE, Beckwith JB, Takashima J, Kelalis P, D\u2019Angio GJ. Treatment outcomes in patients less than 2 years of age with small, stage I, favorable-histology Wilms\u2019 tumors: a report from the National Wilms\u2019 Tumor Study. J Clin Oncol. 1993;11(1):91\u20135.","journal-title":"J Clin Oncol"},{"issue":"3","key":"323_CR22","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1097\/SLA.0b013e3181c0e5d7","volume":"251","author":"RC Shamberger","year":"2010","unstructured":"Shamberger RC, Anderson JR, Breslow NE, Perlman EJ, Beckwith JB, Ritchey ML, et al. Long-term outcomes of infants with very low risk Wilms tumor treated with surgery alone on national Wilms Tumor study-5. Ann Surg. 2010;251(3):555\u20138.","journal-title":"Ann Surg"},{"issue":"17","key":"323_CR23","doi-asserted-by":"publisher","first-page":"3719","DOI":"10.1200\/JCO.2001.19.17.3719","volume":"19","author":"DM Green","year":"2001","unstructured":"Green DM, Breslow NE, Beckwith JB, Ritchey ML, Shamberger RC, Haase GM, et al. Treatment With nephrectomy only for small, stage I\/favorable histology Wilms\u2019 tumor: a report from the national Wilms\u2019 tumor study group. J Clin Oncol. 2001;19(17):3719\u201324.","journal-title":"J Clin Oncol"},{"issue":"8","key":"323_CR24","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1200\/JCO.2004.08.008","volume":"22","author":"DM Green","year":"2004","unstructured":"Green DM. The treatment of stages I\u2013IV favorable histology Wilms\u2019 tumor. J Clin Oncol. 2004;22(8):1366\u201372.","journal-title":"J Clin Oncol"},{"issue":"4","key":"323_CR25","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1097\/SLA.0000000000001716","volume":"265","author":"CV Fernandez","year":"2017","unstructured":"Fernandez CV, Perlman EJ, Mullen EA, Chi Y-Y, Hamilton TE, Gow KW, et al. Clinical outcome and biological predictors of relapse after nephrectomy only for very low-risk Wilms tumor: a report from children\u2019s oncology group AREN0532. Ann Surg. 2017;265(4):835\u201340.","journal-title":"Ann Surg"},{"issue":"6","key":"323_CR26","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1200\/JCO.2010.31.5192","volume":"29","author":"EJ Perlman","year":"2011","unstructured":"Perlman EJ, Grundy PE, Anderson JR, Jennings LJ, Green DM, Dome JS, et al. WT1 mutation and 11P15 loss of heterozygosity predict relapse in very low-risk Wilms tumors treated with surgery alone: a children\u2019s oncology group study. J Clin Oncol. 2011;29(6):698\u2013703.","journal-title":"J Clin Oncol"},{"issue":"9","key":"323_CR27","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1200\/JCO.1984.2.9.1028","volume":"2","author":"B Jones","year":"1984","unstructured":"Jones B, Breslow NE, Takashima J. Toxic deaths in the Second National Wilms\u2019 tumor study. J Clin Oncol. 1984;2(9):1028\u201333.","journal-title":"J Clin Oncol"},{"issue":"11","key":"323_CR28","doi-asserted-by":"publisher","first-page":"2721","DOI":"10.1002\/1097-0142(19920601)69:11<2721::AID-CNCR2820691115>3.0.CO;2-G","volume":"69","author":"MJ Coppes","year":"1992","unstructured":"Coppes MJ, Tournade MF, Lemerle J, Weitzman S, Rey A, Burger D, et al. Preoperative care of infants with nephroblastoma the international society of pediatric oncology 6 experience. Cancer. 1992;69(11):2721\u20135.","journal-title":"Cancer"},{"issue":"2","key":"323_CR29","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1002\/1097-0142(19880715)62:2<270::AID-CNCR2820620208>3.0.CO;2-B","volume":"62","author":"DM Green","year":"1988","unstructured":"Green DM, Finklestein JZ, Norkool P, D\u2019Angio JG. Severe hepatic toxicity after treatment with single-dose dactinomycin and vincristine. A report of the national Wilms\u2019 tumor study. Cancer. 1988;62(2):270\u20133.","journal-title":"Cancer"},{"issue":"4","key":"323_CR30","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1002\/(SICI)1096-911X(199710)29:4<245::AID-MPO2>3.0.CO;2-M","volume":"29","author":"G Bisogno","year":"1997","unstructured":"Bisogno G, Kraker JD, Weirich A, Masiero L, Ludwig R, Tournade MF, et al. Veno-occlusive disease of the liver in children treated for Wilms tumor. Med Pediatric Oncol. 1997;29(4):245\u201351.","journal-title":"Med Pediatric Oncol"},{"issue":"2","key":"323_CR31","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1002\/1097-0142(197608)38:2<633::AID-CNCR2820380203>3.0.CO;2-S","volume":"38","author":"GJ D\u2019Angio","year":"1976","unstructured":"D\u2019Angio GJ, Evans AE, Breslow N, Beckwith B, Bishop H, Feigl P, et al. The treatment of Wilms\u2019 tumor: results of the national Wilms\u2019 tumor study. Cancer. 1976;38(2):633\u201346.","journal-title":"Cancer"},{"issue":"2","key":"323_CR32","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1136\/adc.53.2.112","volume":"53","author":"Medical Research Council\u2019s Working Party on Embryonal Tumours in C","year":"1978","unstructured":"Medical Research Council\u2019s Working Party on Embryonal Tumours in C. Management of nephroblastoma in childhood: clinical study of two forms of maintenance chemotherapy. Arch Dis Child. 1978;53(2):112\u20139.","journal-title":"Arch Dis Child"},{"issue":"1","key":"323_CR33","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1200\/JCO.1995.13.1.124","volume":"13","author":"J Pritchard","year":"1995","unstructured":"Pritchard J, Imeson J, Barnes J, Cotterill S, Gough D, Marsden HB, et al. Results of the United Kingdom Children\u2019s Cancer Study Group first Wilms\u2019 tumor study. J Clin Oncol. 1995;13(1):124\u201333.","journal-title":"J Clin Oncol"},{"issue":"17","key":"323_CR34","doi-asserted-by":"publisher","first-page":"3269","DOI":"10.1200\/JCO.2003.01.062","volume":"21","author":"K Pritchard-Jones","year":"2003","unstructured":"Pritchard-Jones K, Kelsey A, Vujanic G, Imeson J, Hutton C, Mitchell C. Older age is an adverse prognostic factor in stage I, favorable histology Wilms\u2019 tumor treated with vincristine monochemotherapy: a study by the united kingdom children\u2019s cancer study group, Wilm\u2019s Tumor Working Group. J Clin Oncol. 2003;21(17):3269\u201375.","journal-title":"J Clin Oncol"},{"issue":"1","key":"323_CR35","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.yapd.2012.04.001","volume":"59","author":"AM Davidoff","year":"2012","unstructured":"Davidoff AM. Wilms tumor. Adv Pediatrics. 2012;59(1):247\u201367.","journal-title":"Adv Pediatrics"},{"issue":"26","key":"323_CR36","doi-asserted-by":"publisher","first-page":"3189","DOI":"10.1200\/JCO.2015.66.1140","volume":"34","author":"EJ Gratias","year":"2016","unstructured":"Gratias EJ, Dome JS, Jennings LJ, Chi Y-Y, Tian J, Anderson J, et al. Association of chromosome 1q gain with inferior survival in favorable-histology Wilms tumor: a report from the Children\u2019s Oncology Group. J Clin Oncol. 2016;34(26):3189\u201394.","journal-title":"J Clin Oncol"},{"issue":"7","key":"323_CR37","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1002\/pbc.22396","volume":"54","author":"FA Lindsay","year":"2010","unstructured":"Lindsay FA, Shamberger RC, Henderson TO, Lisa D. Decision analysis to compare treatment strategies for stage I\/favorable histology Wilms tumor. Pediatric Blood Cancer. 2010;54(7):879\u201384.","journal-title":"Pediatric Blood Cancer."},{"issue":"7","key":"323_CR38","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1002\/pbc.22505","volume":"54","author":"K Pritchard-Jones","year":"2010","unstructured":"Pritchard-Jones K. Nephrectomy-only for Wilms tumour: negotiating the tangled web requires multi-professional input. Pediatric Blood Cancer. 2010;54(7):865\u20136.","journal-title":"Pediatric Blood Cancer"},{"issue":"8","key":"323_CR39","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.2217\/pgs.14.68","volume":"15","author":"F Ceppi","year":"2014","unstructured":"Ceppi F, Langlois-Pelletier C, Gagn\u00e9 V, Rousseau J, Ciolino C, Lorenzo SD, et al. Polymorphisms of the vincristine pathway and response to treatment in children with childhood acute lymphoblastic leukemia. Pharmacogenomics. 2014;15(8):1105\u201316.","journal-title":"Pharmacogenomics."},{"issue":"3","key":"323_CR40","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.clpt.2004.05.007","volume":"76","author":"SLA Plasschaert","year":"2004","unstructured":"Plasschaert SLA, Groninger E, Boezen M, Kema I, Vries EGE, Uges D, et al. Influence of functional polymorphisms of the MDR1 gene on vincristine pharmacokinetics in childhood acute lymphoblastic Leukemia. Clin Pharmacol Ther. 2004;76(3):220\u20139.","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"323_CR41","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1038\/tpj.2014.81","volume":"15","author":"J Gregers","year":"2015","unstructured":"Gregers J, Gr\u00e9en H, Christensen IJ, Dalhoff K, Schroeder H, Carlsen N, et al. Polymorphisms in the ABCB1 gene and effect on outcome and toxicity in childhood acute lymphoblastic leukemia. Pharmacogenomics J. 2015;15(4):372\u20139.","journal-title":"Pharmacogenomics J"},{"issue":"5","key":"323_CR42","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1111\/bcp.12878","volume":"81","author":"C Walsh","year":"2016","unstructured":"Walsh C, Bonner JJ, Johnson TN, Neuhoff S, Ghazaly EA, Gribben JG, et al. Development of a physiologically based pharmacokinetic model of actinomycin D in children with cancer. Br J Clin Pharmacol. 2016;81(5):989\u201398.","journal-title":"Br J Clin Pharmacol"},{"issue":"16","key":"323_CR43","doi-asserted-by":"publisher","first-page":"5893","DOI":"10.1158\/1078-0432.CCR-04-2546","volume":"11","author":"GJ Veal","year":"2005","unstructured":"Veal GJ, Cole M, Errington J, Parry A, Hale J, Pearson ADJ, et al. Pharmacokinetics of Dactinomycin in a pediatric patient population: a United Kingdom Children\u2019s Cancer Study Group Study. Clin Cancer Res. 2005;11(16):5893\u20139.","journal-title":"Clin Cancer Res"},{"issue":"22","key":"323_CR44","doi-asserted-by":"publisher","first-page":"6800","DOI":"10.1158\/1078-0432.CCR-09-0312","volume":"15","author":"ST Sredni","year":"2009","unstructured":"Sredni ST, Gadd S, Huang C-C, Breslow N, Grundy P, Green DM, et al. Subsets of very low risk Wilms tumor show distinctive gene expression, histologic, and clinical features. Clin Cancer Res. 2009;15(22):6800\u20139.","journal-title":"Clin Cancer Res"},{"issue":"9999","key":"323_CR45","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1016\/S0140-6736(14)62395-3","volume":"386","author":"K Pritchard-Jones","year":"2015","unstructured":"Pritchard-Jones K, Bergeron C, de Camargo B, van den Heuvel-Eibrink MM, Acha T, Godzinski J, et al. Omission of doxorubicin from the treatment of stage II\u2013III, intermediate-risk Wilms\u2019 tumour (SIOP WT 2001): an open-label, non-inferiority, randomised controlled trial. Lancet. 2015;386(9999):1156\u201364.","journal-title":"Lancet"},{"key":"323_CR46","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1038\/nrurol.2017.163","volume":"14","author":"MM Heuvel-Eibrink van den","year":"2017","unstructured":"van den Heuvel-Eibrink MM, Hol JA, Pritchard-Jones K, van Tinteren H, Furtw\u00e4ngler R, Verschuur AC, et al. Rationale for the treatment of Wilms tumour in the UMBRELLA SIOP\u2013RTSG 2016 protocol. Nature Rev Urol. 2017;14:743.","journal-title":"Nature Rev Urol"},{"issue":"26","key":"323_CR47","doi-asserted-by":"publisher","first-page":"3195","DOI":"10.1200\/JCO.2015.66.0001","volume":"34","author":"T Chagtai","year":"2016","unstructured":"Chagtai T, Zill C, Dainese L, Wegert J, Savola S, Popov S, et al. Gain of 1q As a prognostic biomarker in Wilms Tumors (WTs) treated with preoperative chemotherapy in the International Society of Paediatric Oncology (SIOP) WT 2001 Trial: A SIOP Renal Tumours Biology Consortium Study. J Clin Oncol. 2016;34(26):3195\u2013203.","journal-title":"J Clin Oncol"},{"key":"323_CR48","first-page":"3","volume":"14","author":"F Spreafico","year":"2016","unstructured":"The SRTSG, Spreafico F, van den Heuvel-Eibrink MM, Pritchard-Jones K, Bergeron C, Godzinski J, et al. Paediatric renal tumours: perspectives from the SIOP\u2013RTSG. Nature Rev Urol. 2016;14:3.","journal-title":"Nature Rev Urol"},{"issue":"6","key":"323_CR49","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1002\/pbc.24419","volume":"60","author":"JS Dome","year":"2013","unstructured":"Dome JS, Fernandez CV, Mullen EA, Kalapurakal JA, Geller JI, Huff V, et al. Children\u2019s Oncology Group\u2019s 2013 blueprint for research: renal tumors. Pediatric Blood Cancer. 2013;60(6):994\u20131000.","journal-title":"Pediatric Blood Cancer"},{"key":"323_CR50","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.ebiom.2016.05.029","volume":"9","author":"GD Cresswell","year":"2016","unstructured":"Cresswell GD, Apps JR, Chagtai T, Mifsud B, Bentley CC, Maschietto M, et al. Intra-tumor genetic heterogeneity in Wilms Tumor: clonal evolution and clinical implications. EBioMedicine. 2016;9:120\u20139.","journal-title":"EBioMedicine"},{"issue":"2","key":"323_CR51","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.ccell.2015.01.003","volume":"27","author":"AL Walz","year":"2015","unstructured":"Walz AL, Ooms A, Gadd S, Gerhard DS, Smith MA, Guidry Auvil JM, et al. Recurrent DGCR8, DROSHA, and SIX homeodomain mutations in favorable histology Wilms tumors. Cancer Cell. 2015;27(2):286\u201397.","journal-title":"Cancer Cell"},{"issue":"8","key":"323_CR52","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1593\/neo.12714","volume":"14","author":"S Gadd","year":"2012","unstructured":"Gadd S, Huff V, Huang C-C, Ruteshouser EC, Dome JS, Grundy PE, et al. Clinically relevant subsets identified by gene expression patterns support a revised ontogenic model of Wilms tumor: a Children\u2019s Oncology Group Study. Neoplasia (New York, NY). 2012;14(8):742\u201356.","journal-title":"Neoplasia (New York, NY)"},{"issue":"7","key":"323_CR53","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/s41568-018-0007-6","volume":"18","author":"J Drost","year":"2018","unstructured":"Drost J, Clevers H. Organoids in cancer research. Nature Rev Cancer. 2018;18(7):407\u201318.","journal-title":"Nature Rev Cancer"},{"issue":"6","key":"323_CR54","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1242\/dev.140566","volume":"144","author":"J Drost","year":"2017","unstructured":"Drost J, Clevers H. Translational applications of adult stem cell-derived organoids. Development. 2017;144(6):968\u201375.","journal-title":"Development"},{"issue":"7","key":"323_CR55","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.ejca.2011.05.025","volume":"48","author":"AMJB Smets","year":"2012","unstructured":"Smets AMJB, Tinteren HV, Bergeron C, Camargo BD, Graf N, Pritchard-Jones K, et al. The contribution of chest CT-scan at diagnosis in children with unilateral Wilms\u2019 tumour. Results of the SIOP 2001 study. Eur J Cancer. 2012;48(7):1060\u20135.","journal-title":"Eur J Cancer."},{"issue":"4","key":"323_CR56","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1002\/pbc.24123","volume":"59","author":"PE Grundy","year":"2012","unstructured":"Grundy PE, Green DM, Dirks AC, Berendt AE, Breslow NE, Anderson JR, et al. Clinical significance of pulmonary nodules detected by CT and Not CXR in patients treated for favorable histology Wilms tumor on national Wilms tumor studies-4 and 5: a report from the Children\u2019s Oncology Group. Pediatric Blood Cancer. 2012;59(4):631\u20135.","journal-title":"Pediatric Blood Cancer"},{"issue":"12","key":"323_CR57","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1200\/JCO.2002.02.147","volume":"20","author":"CM Owens","year":"2002","unstructured":"Owens CM, Veys PA, Pritchard J, Levitt G, Imeson J, Dicks-Mireaux C. Role of chest computed tomography at diagnosis in the management of Wilms\u2019 tumor: a study by the United Kingdom Children\u2019s Cancer Study Group. J Clin Oncol. 2002;20(12):2768\u201373.","journal-title":"J Clin Oncol"},{"issue":"16","key":"323_CR58","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1200\/JCO.2017.77.1931","volume":"36","author":"DB Dix","year":"2018","unstructured":"Dix DB, Seibel NL, Chi Y-Y, Khanna G, Gratias E, Anderson JR, et al. Treatment of stage IV favorable histology Wilms tumor with lung metastases: a report from the Children\u2019s Oncology Group AREN0533 Study. J Clin Oncol. 2018;36(16):1564\u201370.","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"323_CR59","doi-asserted-by":"publisher","first-page":"10032","DOI":"10.1200\/jco.2014.32.15_suppl.10032","volume":"32","author":"NC Daw","year":"2014","unstructured":"Daw NC, Anderson JR, Hoffer FA, Geller JI, Kalapurakal JA, Perlman EJ, et al. A phase 2 study of vincristine and irinotecan in metastatic diffuse anaplastic Wilms tumor: results from the Children\u2019s Oncology Group AREN0321 study. J Clin Oncol. 2014;32(15_suppl):10032.","journal-title":"J Clin Oncol."},{"issue":"28","key":"323_CR60","doi-asserted-by":"publisher","first-page":"3533","DOI":"10.1200\/JCO.2011.35.8747","volume":"30","author":"A Verschuur","year":"2012","unstructured":"Verschuur A, Tinteren HV, Graf N, Bergeron C, Sandstedt B, Kraker JD. Treatment of pulmonary metastases in children with stage IV nephroblastoma with risk-based use of pulmonary radiotherapy. J Clin Oncol. 2012;30(28):3533\u20139.","journal-title":"J Clin Oncol"},{"issue":"1","key":"323_CR61","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1097\/SLA.0b013e318222015e","volume":"254","author":"SW Warmann","year":"2011","unstructured":"Warmann SW, Furtw\u00e4ngler R, Blumenstock G, Armeanu S, Nourkami N, Leuschner I, et al. Tumor biology influences the prognosis of nephroblastoma patients with primary pulmonary metastases: results from SIOP 93-01\/GPOH and SIOP 2001\/GPOH. Ann Surg. 2011;254(1):155\u201362.","journal-title":"Ann Surg"},{"issue":"8","key":"323_CR62","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1200\/JCO.1993.11.8.1478","volume":"11","author":"F Pein","year":"1993","unstructured":"Pein F, Pinkerton R, Tournade MF, Brunat-Mentigny M, Levitt G, Margueritte G, et al. Etoposide in relapsed or refractory Wilms\u2019 tumor: a phase II study by the French Society of Pediatric Oncology and the United Kingdom Children\u2019s Cancer Study Group. J Clin Oncol. 1993;11(8):1478\u201381.","journal-title":"J Clin Oncol"},{"issue":"5","key":"323_CR63","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1200\/JCO.1994.12.5.931","volume":"12","author":"F Pein","year":"1994","unstructured":"Pein F, Tournade MF, Zucker JM, Brunat-Mentigny M, Deville A, Boutard P, et al. Etoposide and carboplatin: a highly effective combination in relapsed or refractory Wilms\u2019 tumor\u2014a phase II study by the French Society of Pediatric Oncology. J Clin Oncol. 1994;12(5):931\u20136.","journal-title":"J Clin Oncol"},{"issue":"5","key":"323_CR64","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1200\/JCO.1988.6.5.793","volume":"6","author":"MF Tournade","year":"1988","unstructured":"Tournade MF, Lemerle J, Brunat-Mentigny M, Bachelot C, Roche H, Taboureau O, et al. Ifosfamide is an active drug in Wilms\u2019 tumor: a phase II study conducted by the French Society of Pediatric Oncology. J Clin Oncol. 1988;6(5):793\u20136.","journal-title":"J Clin Oncol"},{"issue":"4","key":"323_CR65","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1002\/mpo.2950220409","volume":"22","author":"B Camargo De","year":"1994","unstructured":"De Camargo B, Melaragno R, Silva NSE, Mendoncla N, Alvares MN, Morinaka E, et al. Phase II study of carboplatin as a single drug for relapsed Wilms\u2019 tumor: experience of the Brazilian Wilms\u2019 tumor study group. Med Pediatric Oncol. 1994;22(4):258\u201360.","journal-title":"Med Pediatric Oncol"},{"issue":"1","key":"323_CR66","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.ejca.2012.07.010","volume":"49","author":"TC Ha","year":"2013","unstructured":"Ha TC, Spreafico F, Graf N, Dallorso S, Dome JS, Malogolowkin M, et al. An international strategy to determine the role of high dose therapy in recurrent Wilms\u2019 tumour. Eur J Cancer. 2013;49(1):194\u2013210.","journal-title":"Eur J Cancer"},{"issue":"2","key":"323_CR67","doi-asserted-by":"publisher","first-page":"e26849","DOI":"10.1002\/pbc.26849","volume":"65","author":"JA Hol","year":"2018","unstructured":"Hol JA, den Heuvel-Eibrink MM, Graf N, Pritchard-Jones K, Brok J, Tinteren H, et al. Irinotecan for relapsed Wilms tumor in pediatric patients: SIOP experience and review of the literature\u2014a report from the SIOP Renal Tumor Study Group. Pediatric Blood Cancer. 2018;65(2):e26849.","journal-title":"Pediatric Blood Cancer"},{"issue":"4","key":"323_CR68","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1002\/pbc.25357","volume":"62","author":"AMC Mavinkurve-Groothuis","year":"2015","unstructured":"Mavinkurve-Groothuis AMC, van den Heuvel-Eibrink MM, Tytgat GA, van Tinteren H, Vujanic G, Pritchard-Jones KLP, et al. Treatment of relapsed Wilms tumour (WT) patients: experience with topotecan. A report from the SIOP Renal Tumour Study Group (RTSG). Pediatric Blood Cancer. 2015;62(4):598\u2013602.","journal-title":"Pediatric Blood Cancer"},{"issue":"21","key":"323_CR69","doi-asserted-by":"publisher","first-page":"3130","DOI":"10.1200\/JCO.2007.10.9298","volume":"25","author":"ML Metzger","year":"2007","unstructured":"Metzger ML, Stewart CF III, Freeman BB, Billups CA, Hoffer FA, Wu J, et al. Topotecan is active against Wilms\u2019 tumor: results of a multi-institutional phase II study. J Clin Oncol. 2007;25(21):3130\u20136.","journal-title":"J Clin Oncol"},{"issue":"5","key":"323_CR70","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1002\/pbc.20822","volume":"48","author":"DM Green","year":"2007","unstructured":"Green DM, Cotton CA, Malogolowkin M, Breslow NE, Perlman E, Miser J, et al. Treatment of Wilms tumor relapsing after initial treatment with vincristine and actinomycin D: a report from the National Wilms Tumor Study Group. Pediatric Blood Cancer. 2007;48(5):493\u20139.","journal-title":"Pediatric Blood Cancer"},{"issue":"2","key":"323_CR71","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1002\/pbc.21267","volume":"50","author":"M Malogolowkin","year":"2008","unstructured":"Malogolowkin M, Cotton CA, Green DM, Breslow NE, Perlman E, Miser J, et al. Treatment of Wilms tumor relapsing after initial treatment with vincristine, actinomycin D, and doxorubicin. A report from the National Wilms Tumor Study Group. Pediatric Blood Cancer. 2008;50(2):236\u201341.","journal-title":"Pediatric Blood Cancer."},{"key":"323_CR72","unstructured":"Hale J, Hobson R, Moroz V, Sartori P. Results of UK children\u2019s cancer and leukemia group (CCLG) protocol for relapsed Wilms tumor (UKWR): unified relapse strategy improves outcome. In: Proceeding of the 40th Meeting of International Society of Pediatric Oncology (Abstract O154). 2008:16."},{"issue":"18","key":"323_CR73","doi-asserted-by":"publisher","first-page":"8014","DOI":"10.18632\/oncotarget.2485","volume":"5","author":"M Maschietto","year":"2014","unstructured":"Maschietto M, Charlton J, Perotti D, Radice P, Geller JI, Pritchard-Jones K, et al. The IGF signalling pathway in Wilms tumours\u2014A report from the ENCCA Renal Tumours Biology-driven drug development workshop. Oncotarget. 2014;5(18):8014\u201326.","journal-title":"Oncotarget"},{"issue":"12","key":"323_CR74","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.1158\/1535-7163.MCT-13-0335","volume":"12","author":"D Perotti","year":"2013","unstructured":"Perotti D, Hohenstein P, Bongarzone I, Maschietto M, Weeks M, Radice P, et al. Is Wilms tumor a candidate neoplasia for treatment with WNT\/\u03b2-catenin pathway modulators?\u2014a report from the renal tumors biology-driven drug development workshop. Mol Cancer Ther. 2013;12(12):2619\u201327.","journal-title":"Mol Cancer Ther"},{"issue":"9","key":"323_CR75","doi-asserted-by":"publisher","first-page":"7232","DOI":"10.18632\/oncotarget.3377","volume":"6","author":"RD Williams","year":"2015","unstructured":"Williams RD, Chagtai T, Alcaide-German M, Apps J, Wegert J, Popov S, et al. Multiple mechanisms of MYCN dysregulation in Wilms tumour. Oncotarget. 2015;6(9):7232\u201343.","journal-title":"Oncotarget"},{"key":"323_CR76","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.ejca.2017.04.005","volume":"79","author":"J Brok","year":"2017","unstructured":"Brok J, Pritchard-Jones K, Geller JI, Spreafico F. Review of phase I and II trials for Wilms\u2019 tumour\u2014can we optimise the search for novel agents? Eur J Cancer. 2017;79:205\u201313.","journal-title":"Eur J Cancer"},{"issue":"15_suppl","key":"323_CR77","doi-asserted-by":"publisher","first-page":"10537","DOI":"10.1200\/JCO.2017.35.15_suppl.10537","volume":"35","author":"JI Geller","year":"2017","unstructured":"Geller JI, Pressey JG, Smith MA, Kudgus RA, Schoon R, McGovern RM, et al. ADVL1522: a phase 2 study of IMGN901 (lorvotuzumab mertansine; IND# 126953, NSC# 783609) in children with relapsed or refractory Wilms tumor, rhabdomyosarcoma, neuroblastoma, pleuropulmonary blastoma, malignant peripheral nerve sheath tumor (MPNST), and synovial sarcoma: a Children\u2019s Oncology Group study. J Clin Oncol. 2017;35(15_suppl):10537.","journal-title":"J Clin Oncol"},{"issue":"3","key":"323_CR78","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1200\/JCO.2011.37.4355","volume":"30","author":"S Malempati","year":"2012","unstructured":"Malempati S, Weigel B, Ingle AM, Ahern CH, Carroll JM, Roberts CT, et al. Phase I\/II Trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and ewing sarcoma: a report from the Children\u2019s Oncology Group. J Clin Oncol. 2012;30(3):256\u201362.","journal-title":"J Clin Oncol"},{"issue":"3","key":"323_CR79","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1002\/pbc.24605","volume":"61","author":"B Weigel","year":"2014","unstructured":"Weigel B, Malempati S, Reid JM, Voss SD, Cho SY, Chen HX, et al. Phase 2 trial of cixutumumab in children, adolescents, and young adults with refractory solid tumors: a report from the Children\u2019s Oncology Group. Pediatric Blood Cancer. 2014;61(3):452\u20136.","journal-title":"Pediatric Blood Cancer"},{"issue":"7","key":"323_CR80","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1158\/1078-0432.CCR-14-0595","volume":"21","author":"M Fouladi","year":"2015","unstructured":"Fouladi M, Perentesis JP, Wagner LM, Vinks AA, Reid JM, Ahern C, et al. A phase I study of cixutumumab (IMC-A12) in combination with temsirolimus (CCI-779) in children with recurrent solid tumors: a Children\u2019s Oncology Group Phase I Consortium Report. Clin Cancer Res. 2015;21(7):1558\u201365.","journal-title":"Clin Cancer Res"},{"key":"323_CR81","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ejca.2016.03.084","volume":"62","author":"D Frappaz","year":"2016","unstructured":"Frappaz D, Federico SM, Pearson ADJ, Gore L, Macy ME, DuBois SG, et al. Phase 1 study of dalotuzumab monotherapy and ridaforolimus\u2013dalotuzumab combination therapy in paediatric patients with advanced solid tumours. Eur J Cancer. 2016;62:9\u201317.","journal-title":"Eur J Cancer"},{"issue":"7","key":"323_CR82","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1097\/01.cad.0000217426.82702.74","volume":"17","author":"A Wagner-Bohn","year":"2006","unstructured":"Wagner-Bohn A, Paulussen M, Vieira Pinheiro JP, Gerss J, Stoffregen C, Boos J. Phase II study of gemcitabine in children with solid tumors of mesenchymal and embryonic origin. Anti-Cancer Drugs. 2006;17(7):859\u201364.","journal-title":"Anti-Cancer Drugs"},{"issue":"2","key":"323_CR83","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.ejca.2010.09.015","volume":"47","author":"B Geoerger","year":"2011","unstructured":"Geoerger B, Chisholm J, Le Deley M-C, Gentet J-C, Zwaan CM, Dias N, et al. Phase II study of gemcitabine combined with oxaliplatin in relapsed or refractory paediatric solid malignancies: an innovative therapy for children with Cancer European Consortium Study. Eur J Cancer. 2011;47(2):230\u20138.","journal-title":"Eur J Cancer"},{"issue":"3","key":"323_CR84","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1158\/1078-0432.CCR-10-0738","volume":"17","author":"JM Su","year":"2011","unstructured":"Su JM, Li X-N, Thompson P, Ou C-N, Ingle AM, Russell H, et al. Phase 1 study of valproic acid in pediatric patients with refractory solid or CNS tumors: a Children\u2019s Oncology Group Report. Clin Cancer Res. 2011;17(3):589\u201397.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"323_CR85","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1002\/pbc.24271","volume":"60","author":"JA Muscal","year":"2013","unstructured":"Muscal JA, Thompson PA, Horton TM, Ingle AM, Ahern CH, McGovern RM, et al. A phase I trial of vorinostat and bortezomib in children with refractory or recurrent solid tumors: a Children\u2019s Oncology Group phase I consortium study (ADVL0916). Pediatric Blood Cancer. 2013;60(3):390\u20135.","journal-title":"Pediatric Blood Cancer"},{"issue":"22","key":"323_CR86","doi-asserted-by":"publisher","first-page":"3678","DOI":"10.1200\/JCO.2006.06.4964","volume":"24","author":"M Fouladi","year":"2006","unstructured":"Fouladi M, Furman WL, Chin T III, Freeman BB, Dudkin L, Stewart CF, et al. Phase I study of depsipeptide in pediatric patients with refractory solid Tumors: a Children\u2019s Oncology Group Report. J Clin Oncol. 2006;24(22):3678\u201385.","journal-title":"J Clin Oncol."},{"issue":"4","key":"323_CR87","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1002\/pbc.24794","volume":"61","author":"NJ Robison","year":"2014","unstructured":"Robison NJ, Campigotto F, Chi SN, Manley PE, Turner CD, Zimmerman MA, et al. A phase II trial of a multi-agent oral antiangiogenic (metronomic) regimen in children with recurrent or progressive cancer. Pediatric Blood Cancer. 2014;61(4):636\u201342.","journal-title":"Pediatric Blood Cancer"},{"issue":"21","key":"323_CR88","doi-asserted-by":"publisher","first-page":"3423","DOI":"10.1200\/JCO.2005.03.9271","volume":"24","author":"JG Villablanca","year":"2006","unstructured":"Villablanca JG, Krailo MD, Ames MM, Reid JM, Reaman GH, Reynolds CP. Phase I trial of oral fenretinide in children with high-risk solid tumors: a report from the Children\u2019s Oncology Group (CCG 09709). J Clin Oncol. 2006;24(21):3423\u201330.","journal-title":"J Clin Oncol"},{"issue":"5","key":"323_CR89","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1002\/pbc.21011","volume":"49","author":"PC Adamson","year":"2007","unstructured":"Adamson PC, Matthay KK, O\u2019Brien M, Reaman GH, Sato JK, Balis FM. A phase 2 trial of all-trans-retinoic acid in combination with interferon-\u03b12a in children with recurrent neuroblastoma or Wilms tumor: a Pediatric Oncology Branch, NCI and Children\u2019s Oncology Group Study. Pediatric Blood Cancer. 2007;49(5):661\u20135.","journal-title":"Pediatric Blood Cancer"},{"issue":"21","key":"323_CR90","doi-asserted-by":"publisher","first-page":"6058","DOI":"10.1158\/1078-0432.CCR-11-3251","volume":"18","author":"YP Moss\u00e9","year":"2012","unstructured":"Moss\u00e9 YP, Lipsitz E, Fox E, Teachey DT, Maris JM, Weigel B, et al. Pediatric phase I trial and pharmacokinetic study of MLN8237, an investigational oral selective small-molecule inhibitor of aurora kinase A: a Children\u2019s Oncology Group Phase I Consortium Study. Clin Cancer Res. 2012;18(21):6058\u201364.","journal-title":"Clin Cancer Res"}],"container-title":["Pediatric Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40272-018-0323-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-018-0323-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-018-0323-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,13]],"date-time":"2024-07-13T19:13:38Z","timestamp":1720898018000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40272-018-0323-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,2]]},"references-count":90,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["323"],"URL":"https:\/\/doi.org\/10.1007\/s40272-018-0323-z","relation":{},"ISSN":["1174-5878","1179-2019"],"issn-type":[{"value":"1174-5878","type":"print"},{"value":"1179-2019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,2]]},"assertion":[{"value":"2 January 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"RMO is funded by the Great Ormond Street Hospital Children\u2019s Charity (grant reference W1090). KPJ is funded in part by\u00a0the National Institute for Health Research (NIHR) Great Ormond Street Hospital Biomedical Research Centre, Great Ormond Street Hospital Children\u2019s Charity, Cancer Research UK (grant no. C1188\/A4614) and the Children\u2019s Cancer and Leukaemia Group (Bethany\u2019s Wish, grant reference CCLGA 2017 02).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Radna Minou Oostveen and Kathy Pritchard-Jones have no conflicts of interest that might be relevant to the contents of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}